Association between FAS and FASL Genetic Variants and Risk of Primary Brain Tumor

References

• Permuth-Wey J, Thompson RC, Burton Nabors L, A functional polymorphism in the pre-miR-146a gene isassociated with risk and prognosis in adult glioma. J Neurooncol 2011;105(3):639–46.
   PubMed Web of Science ®Google Scholar
• Fisher JL, Schwartzbaum JA, Wrensch M, Epidemiology of brain tumors. Neurol Clin 2007;25(4):867–90.
   PubMed Web of Science ®Google Scholar
• Hou WG, Ai WB, Bai XG, Genetic variation in the EGFR gene and the risk of glioma in a Chinese Han population. PLoS One 2012;7(5):e37531.
   Web of Science ®Google Scholar
• Marosi C, Hassler M, Roessler K, Meningioma. Crit Rev Oncol Hematol 2008;67(2):153–71.
   PubMed Web of Science ®Google Scholar
• Wrensch M, Fisher JL, Schwartzbaum JA, The molecular epidemiology of gliomas in adults. Neurosurg Focus 2005;19(5):E5.
   PubMedGoogle Scholar
• Gu J, Liu Y, Kyritsis AP, Bondy ML. Molecular epidemiology of primary brain tumors. Neurotherapeutics 2009;6(3):427–35.
   PubMed Web of Science ®Google Scholar
• Fischer U, Meese E. Glioblastoma multiforme: the role of DSB repair between genotype and phenotype. Oncogene 2007; 10;26(56):7809–15.
   PubMed Web of Science ®Google Scholar
• Thompson CB. Apoptosis is the pathogenesis and treatment of disease. Science 1995;267:1456–62.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang LE, Sturgis EM, Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 2006;12(18):5596–602.
   PubMed Web of Science ®Google Scholar
• Ter-Minassian M, Zhai R, Asomaning K, Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 2008;29(11):2147–52.
   PubMed Web of Science ®Google Scholar
• Lorenzo HK, Susin SA. Therapeutic potential of AIF-mediated caspase-independent programmed cell death. Drug Resist Updat 2007;10:235–55.
   PubMed Web of Science ®Google Scholar
• Wang W, Zheng Z, Yu W, Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett 2012;3(3):625–8.
   PubMed Web of Science ®Google Scholar
• Kupcinskas J, Wex T, Bornschein J, Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet 2011;24(12):112.
   Google Scholar
• Zhou RM, Wang N, Chen ZF, Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol 2010; 25(3):555–61.
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K, The role of Fas ligand and transforming growth factor β in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004;100:2281–91.
   PubMed Web of Science ®Google Scholar
• Sung WW, Wang YC, Cheng YW, A polymorphic -844 T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res 2011;17(18):5991–9.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Li WM, Zhao RX, The effects of the polymorphism in exon 3 of the FAS gene on the death of chicken embryos during the incubation period. Anim Genet 2008;39(5):558–60.
   PubMed Web of Science ®Google Scholar
• Chatterjee K, Dandara C, Gyllensten U, A Fas gene polymorphism influences herpes simplex virus type 2 infection in South African women. J Med Virol 2010;82(12): 2082–6.
   PubMed Web of Science ®Google Scholar
• Wu J, Metz C, Xu X, A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003;170:132–8.
   PubMed Web of Science ®Google Scholar
• Zhang X, Miao X, Sun T, Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005;42:479–84.
   PubMed Web of Science ®Google Scholar
• Krippl P, Langsenlehner U, Renner W, Re: polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96: 1478–9.
   PubMed Web of Science ®Google Scholar
• Ueda M, Hung YC, Terai Y, Fas gene promoter –670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol 2005;98:129–33.
   PubMed Web of Science ®Google Scholar
• Sun T, Zhou Y, Li H, FASL –844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 2005;202:967–74.
   PubMed Web of Science ®Google Scholar
• Li C, Larson D, Zhang Z, Polymorphisms of the FAS and FAS ligand genesassociated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 2006;16: 253–63.
   PubMed Web of Science ®Google Scholar
• Sun T, Miao X, Zhang X, Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96:1030–6.
   Google Scholar
• Sibley K, Rollinson S, Allan JM, Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327–30.
   PubMed Web of Science ®Google Scholar
• Yang M, Sun T, Wang L, Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 2008;14:3230–6.
   PubMed Web of Science ®Google Scholar
• Hsu PI, Lu PJ, Wang EM, Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions. Anticancer Res 2008;28:97–103.
   PubMed Web of Science ®Google Scholar
• Qiu LX, Shi J, Yuan H, FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls. Hum Genet 2009;125: 431–5.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Xue H, Gong W, FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 2009;30: 487–93.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Qiu L, Wang M, The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies. Eur J Hum Genet 2009;17:1294–303.
   PubMed Web of Science ®Google Scholar
• Kleihues P, Cavenee WB. In World Health Organization Classification of Tumors: Pathology and Genetics: Tumors of the nervous system. IARC Press: Lyon 2000; 6–7.
   Google Scholar
• Zhang B, Sun T, Xue L, Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007;28:1067–73.
   PubMed Web of Science ®Google Scholar
• Yang S, Miao XP, Zhang XM, Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer. Zhonghua Yi Xue Za Zhi 2005;85:2132–5.
   PubMedGoogle Scholar
• Zhang Z, Wang LE, Sturgis EM, Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 2006;12:5596–602.
   PubMed Web of Science ®Google Scholar
• Zhang H, Sun XF, Synnerstad I, Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J 2007;13:233–7.
   PubMed Web of Science ®Google Scholar
• Park SH, Choi JE, Kim EJ, Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 2006;54: 303–8.
   PubMed Web of Science ®Google Scholar
• Ivansson EL, Gustavsson IM, Magnusson JJ, Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer 2007;121:2451–7.
   PubMed Web of Science ®Google Scholar
• Erdogan M, Karadeniz M, Berdeli A, Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population. J Endocrinol Invest 2007;30:411–16.
   PubMed Web of Science ®Google Scholar
• Lima RT, Busacca S, Almeida GM, MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer 2011;47:163–74..
   PubMed Web of Science ®Google Scholar
• Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer 2011;47(8):1127–37..
   PubMed Web of Science ®Google Scholar
• Sayed D, He M, Hong C, MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem 2010; 285(26): 20281–90.
   PubMed Web of Science ®Google Scholar
• Farazi TA, Hoell JI, Morozov P, MicroRNAs in human cancer. Adv Exp Med Biol 2013;774:1–20..
   PubMed Web of Science ®Google Scholar